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A B S T R A C T
The hallmarks of Parkinson's disease and other synucleinopathies, Tubulin Polymerization Promoting Protein (TPPP/p25)
and α-synuclein (SYN) have two key features: they are disordered and co-enriched/co-localized in brain inclusions. These
Neomorphic Moonlighting Proteins display both physiological and pathological functions due to their interactions with
distinct partners. To achieve the selective targeting of the pathological TPPP/p25-SYN but not the physiological TPPP/
p25-tubulin complex, their interfaces were identified as a specific innovative strategy for the development of anti-Parkin-
son drugs. Therefore, the interactions of TPPP/p25 with tubulin and SYN were characterized which suggested the in-
volvements of the 178–187 aa and 147–156 aa segments in the complexation of TPPP/p25 with tubulin and SYN, respec-
tively. However, various truncated and deletion mutants reduced but did not abolish the interactions except one mutant; in
addition synthetized fragments corresponding to the potential binding segments of TPPP/p25 failed to interact with SYN.
In fact, the studies of the multiple interactions at molecular and cellular levels revealed the high conformational plasticity,
chameleon feature, of TPPP/p25 that ensures exceptional functional resilience; the lack of previously identified binding
segments could be replaced by other segments. The experimental results are underlined by distinct bioinformatics tools.
All these data revealed that although targeting chameleon proteins is a challenging task, nevertheless, the validation of a
drug target can be achieved by identifying the interface of complexes of the partner proteins existing at the given patho-
logical conditions.
© 2016 Published by Elsevier Ltd.
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1. Introduction
The sensing, integrating and coordinating features of eukaryotic
cells are achieved by complex ultrastructural arrays and multifarious
functions of the cytoskeletal network that comprises networks of fi-
brous proteins in a form of microtubules, actin and intermediate fila-
ments. These filamentous polymer structures are highly dynamic and
undergo constant and rapid reorganization during cellular life cycle.
The microtubule system plays a crucial role in brain physiology, as it
is involved in an enormous number of cellular events including cell
differentiation and pathological inclusion formation [1,2]. These var-
ious functions of microtubules are achieved by their decoration with
proteins/enzymes that exert specific effects on the dynamics and the
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organization of the cytoskeleton resulting in distinct functions with
moonlighting features [3]. Moonlighting proteins perform multiple in-
dependent functions originated not from alterations at gene level, but
because of the consequence of altered cellular localization, oligomeric
states or distinct interacting partners [4]. In the case of neomorphic
moonlighting proteins [5], the physiological function can be converted
into a pathological one due to interaction with a different partner pro-
tein in the pathological milieu. The prototype of these neomorphic
moonlighting proteins is the Tubulin Polymerization Promoting Pro-
tein (TPPP/p25) [6].
TPPP/p25 is a Microtubule Associated Protein; its expression is
finely controlled in the human brain [7–9]. It is an intrinsically disor-
dered protein (IDP) without a well-defined 3D structure, whose mid-
dle, highly flexible CORE region is straddled by the unstructured N-
and C-termini [10]. TPPP/p25 modulates the dynamics and stabil-
ity of the microtubule system, where it is primarily engaged in the
development of projections of oligodendrocytes that are responsible
for the ensheathment of axons [7,9,11]. A couple of specific bind-
ing domains in the disordered TPPP/p25 have been identified both se-
quentially and experimentally such as a zinc finger motif, consensus
GTP binding domain, phosphorylation sites, and the functional con-
sequences of these sites have been established ( [12] and references
therein). The non-physiological expression levels of this IDP lead to
http://dx.doi.org/10.1016/j.bbadis.2016.09.017
0925-4439/© 2016 Published by Elsevier Ltd.
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distinct CNS diseases such as glioma (brain tumor) [13], multiple scle-
rosis (demyelination) [14,15] or synucleinopathies (pathological in-
clusions) [16]. In fact, TPPP/p25 is able to induce α-synuclein (SYN)
aggregation [17] in vitro; however, its overexpression and co-localiza-
tion with SYN in human brain is a characteristic symptom of Parkin-
son's disease [16], thus we have suggested TPPP/p25 as a biomarker
of synucleinopathies [16]. Nevertheless, we have also detected TPPP/
p25 and SYN-enriched inclusions in the case of diffuse Lewy body
dementia with Alzheimer's disease as well [18].
The disordered SYN is considered as a classic chameleon protein
[19]. Similarly as chameleons change color to mimic their environ-
ment, protein chameleons have high structural plasticity and are able
to adopt various conformations in a template-dependent manner [19].
Although the intrinsically disordered SYN is predominantly unfolded
at physiological conditions, in response to changes in its environment
it is capable of adopting structurally unrelated conformations rang-
ing from intrinsically disordered form to various partially folded con-
formations with different contents of secondary structural elements
induced by low pH, high temperature, organic solvents, membranes,
agrochemicals, or metal ions [19,20]. The structural properties of SYN
have been extensively characterized under a variety of conditions
[21–29]. Despite the fact that the unstructured C-terminal segment (45
aa) is involved in the modulation of SYN aggregation at extreme in
vitro conditions, yet a terminal 30-residue-long peptide was found to
be ineffective as a competitor in aggregation processes, indicating its
chameleon nature [19].
Although knowledge on various mechanisms underlying Parkin-
son's disease and other synucleinopathies has been greatly expanded
over the last decades, the pathomechanism is still not well-under-
stood [30–32]. Different mechanisms have been suggested such as
mitochondrial dysfunction, cytoskeletal alterations, enhanced oxida-
tive stress or impairment of protein clearance pathways. SYN plays
multiple pivotal roles in these diseases, nowadays its small, solu-
ble oligomeric forms with beta-sheet conformation are considered the
most toxic species [30,32,33]. To target SYN toxicity, the current
strategies focus on its increased expression level (by gene silencing),
aggregation (by anti-aggregation compounds), defective clearance (by
autophagy inducers), and/or cell-to-cell propagation of its neurotoxic
conformers (by immunotherapy, degrading enzymes) [30,34].
Recently we have suggested a new strategy for the therapeutic
treatment of Parkinson's disease by targeting the interface of the
pathological TPPP/p25-SYN complex without influencing the phys-
iological interaction of TPPP/p25 with tubulin/microtubules [35,36].
The distinct interface of the physiological and pathological complexes
is a crucial point in our drug targeting strategy. Our analysis revealed
that the 147KAPIISGVTK156 segment in the flexible CORE region
of TPPP/p25 and the 126EMPSEEGYQDYEPEA140 segment of the
C-terminus of SYN are involved in the formation of the interface of
their pathological complex [36]. Massive intracellular aggregation of
the N- and C-terminally-truncated TPPP/p25 and SYN or its fragments
was established. This finding initiated our research aiming at the eluci-
dation of the nature of the TPPP/p25-SYN interaction, in order to bet-
ter understand how these two disordered proteins generate oligomeric,
soluble pathological associates acting as the fatal species that lead to
the development of inclusions observed under pathological conditions.
It has been documented that these small, soluble and highly ex-
pressed moonlighting proteins are unstructured under physiological
conditions, and they frequently display multiple functions due to their
conformational plasticity and their ability to act as protein chameleons
[19]. In this work, we established the chameleon nature of TPPP/
p25 using various truncated and deletion mutants/fragments
in the interaction and functional studies and revealed a main challenge
associated with the design of drugs targeting such chameleon proteins.
2. Materials and methods
2.1. Antibodies, peptides
The following antibodies were used: mouse monoclonal tubulin
antibody (Sigma T9026, clone DM1A), mouse monoclonal SYN anti-
body against the epitope of 121–125 aa (Sigma S5566, clone Syn211)
and rat polyclonal TPPP/p25 antibody [16]. The peptides BF181–183
were synthesized as described in [35].
2.2. DNA manipulations
The internal single and discontinue deletion mutants of TPPP/
p25 were constructed by a polymerase chain reaction (PCR) based
on overlap extension method [37] as described below. The first PCR
generated two fragments using two pairs of primers: primer1 (for-
ward) and primer2 (reverse) or primer5 (reverse) or primer7 (reverse)
or primer9 (reverse) or primer11 (reverse) and primer3 (forward)
or primer6 (forward) or primer8 (forward) or primer10 (forward) or
primer12 (forward) and primer4 (reverse) and pET21c–TPPP/p25 as a
template (Table 1).
The two fragments were then used as the template for a second
PCR with primer pair primer1 (forward) and primer4 (reverse). The
fragments obtained from the second PCR were inserted into the NdeI/
XhoI sites of pET21c to generate the ∆ 147–156 TPPP/p25 (SL) or
∆ 142–162 TPPP/p25 (LL) or ∆ 59–62 TPPP/p25 (ML) or ∆ 178–187
TPPP/p25 (TL) or ∆ 112–144 TPPP/p25 (CL) mutants (Table 2). For
the double deletion mutant (DL), the first PCR generated two frag-
ments using two pairs of primers: primer1 (forward) and primer7 (re-
verse) and primer8 (forward) and primer4 (reverse) and SL as a tem-
plate.
The double truncated TPPP/p25 (pET21c–TPPP/p25
Δ3–43/Δ175–219, DT) was prepared and purified as described previ-
ously [35]. The double truncated mini loop TPPP/p25 (DTML), dou-
ble truncated small loop TPPP/p25 (DTSL) and double truncated dou-
ble loop TPPP/p25 (DTDL) were amplified by PCR using the follow-
ing primer pairs: primer13 and primer17 and ML, SL or DL as a tem-
plate. After digestion with NdeI and XhoI restriction enzymes, inserts
were ligated into pET21c vector (Novagen).
The human TPPP/p25 peptides corresponding to residues 43–90
(rfr-1) and 142–187 (rfr-2) with a His-tag were amplified by PCR us-
ing forward primer primer13 or primer15 and reverse primer primer14
or primer16 and human full length TPPP/p25 plasmid [11] as a tem-
plate. After digestion with NdeI and XhoI restriction enzymes, in-
serts were ligated into pET15b vector (Novagen). The human TPPP/
p25 peptide corresponding to residues 142–219 C-terminal without
178–187 segment (rfr-3) with a His-tag was amplified by PCR using
primer15 (forward) and primer4 (reverse) with TL plasmid as a tem-
plate. Correct insertion of all these plasmids was verified by DNA se-
quencing.
2.3. Bimolecular fluorescence complementation (BiFC) plasmids
The BiFC plasmids (pBiFC-VN1–173, pBiFC-VC155–238) were
the gift of Prof. Péter Várnai (Semmelweis University, Budapest). To
insert the full length TPPP/p25 cDNA in either the pBiFC-VN1–173
or pBiFC-VC155–238 the following primers for PCR amplification
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Table 1
TPPP/p25 primers.
Short name Long name Primer sequence
primer1 TPPP/p25 5′ wt F AGATACACATATGGCTGACAAGGCTAAGC
primer2 ∆ 147–156 TPPP/p25 R GGGCGACGAGATGGCGCCCTCGATGAGCCTGTG
primer3 ∆ 147–156 TPPP/p25 F AGGCTCATCGAGGGCGCCATCTCGTCGCCCACAG
primer4 TPPP/p25 3′ wt R GTGCTCGAGCTTGCCCCCTTGC
primer5 ∆ 142–161 TPPP/p25 R GAGGTTCGCGAGGTGCACACAGTGTCGAGGCTC
primer6 ∆ 142–161 TPPP/p25 F CGTTCGCGAGGTGCACACAGTGTCGAGGCTCACG
primer7 ∆ 59–62 TPPP/p25 R TCCCGGTGGCCCTGGCGTCAAAGCGCCGGAAGGCCTCCTC
primer8 ∆ 59–62 TPPP/p25 F AGGAGGCCTTCCGGCGCTTTGACGCCAGGGCCACCGGGAG
primer9 ∆ 178–187 TPPP/p25 R CACGCGGCCAGCCTTGCCCTTGTGGGAGCCCGTGAAC
primer10 ∆ 178–187 TPPP/p25 F ACGGGCTCCCACAAGGGCAAGGCTGGCCGCGTGGATC
primer11 ∆ 112–144 TPPP/p25R GATGATGGGCGCCTTGCCCTCGGTGATGGTCCGGCAAGACTTC
primer12 ∆ 112–144 TPPP/p25 F GAAGTCTTGCCGGACCATCACCGAGGGCAAGGCGCCCATCATC
primer13 TPPP/p25 truncated F GAGATATACATATGGCTGCATCCCCTGAGCTC
primer14 43–90 TPPP/p25 R TGACCTCGAGGTTCCTGCCGTCGATCACCTGG
primer15 142–187 TPPP/p25 F GAGCATATGAGGCTCATCGAGGGCAAGGCGCCC
primer16 142–187 TPPP/p25 R AGCCTCGAGCTTGCCCTTGCCAGAGGGGTCGAAGCGC
primer17 TPPP/p25 truncated R GGTGCTCGAGGCCCGTGAACTTGGTGGTGTC
Table 2
TPPP/p25 variants: truncated and deletion mutants as well as fragments.
Long name Sequence Abbreviation
1 Full length 1–219 FL
2 Mini loop Δ59–62 ML
3 Small loop Δ147–156 SL
4 Double loop Δ59–62/Δ147–156 DL
5 Large loop Δ142–161 LL
6 Tubulin loop Δ178–187 TL
7 Central loop Δ112–144 CL
8 Double truncated Δ3–43/Δ175–219 DT
9 Double truncated
mini loop
Δ3–43/Δ175–219 + Δ59–62 DTML
10 Double truncated
small loop
Δ3–43/Δ175–219 + Δ147–156 DTSL
11 Double truncated
double loop
Δ3–43/Δ175–219 + Δ59–62/Δ147–156 DTDL
12 Recombinant
fragment 1
43–90 rfr-1
13 Recombinant
fragment 2
142–187 rfr-2
14 Recombinant
fragment 3
142–219, Δ178–187 rfr-3
were used: 5-GAAGGAGCTCGAGATATGGCTGACAAGGC-
TAAGC-3 (forward) and 5-CCGTGGATCCCTACTTGCCCC-
CTTGCACCTTCTGGTCGTAGG-3 (reverse). The PCR product, fol-
lowing purification and after digestion with XhoI-BamHI restriction
enzymes, was inserted to XhoI and BamHI sites in the BiFC vectors.
To insert the full length SYN cDNA in either the pBiFC-VN1–173
or pBiFC-VC155–238, the following primers for PCR amplification
were used: 5-ATCTCGAGGCATGGATGTATTCATGAAAGG-3
(forward) and 5-AGAAGATCTTTAGGCTTCAGGTTCG-
TAGTCTTGATACC-3 (reverse). The PCR product, following purifi-
cation and after digestion with XhoI-BglII restriction enzymes, was in-
serted to XhoI and BamHI sites in the BiFC vectors. The sequences of
all construct were verified by restriction mapping and sequencing.
2.4. Expression and purification of human recombinant wild type and
mutant TPPP/p25 forms
Human recombinant TPPP/p25 forms and fragments (see Table 2)
possessing His-tags were expressed in E. coli BL21 (DE3) cells and
isolated on HIS-Select™ Cartridge (Sigma-Aldrich) as described pre-
viously [16,35].
In the case of LL, the purification was based on the method de-
scribed in [38]. Briefly, the cell pellet was resuspended in buffer
A (10 mM tris(hydroxymethyl)aminomethane (Tris), 100 mM phos-
phate buffer pH 7.5 containing 50 mM NaCl) with 10 μM
4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, 1 mM ben-
zamidine, 1 μg/ml pepstatin, 1 μg/ml leupeptin and 1 mg/ml lysozyme
(Sigma L7651); and further lysed by sonication. After centrifuga-
tion (25 min, 4 °C, 20,000 g), the pellet was resuspended in buffer
A containing 1 M urea and 1% Triton X-100. After centrifugation
(25 min, 4 °C, 20,000 g), the pellet was resuspended in buffer A con-
taining 8 M guanidine·HCl, sonicated and centrifuged again (25 min,
4 °C, 20,000g). The final supernatant was diluted two-fold with buffer
A, and loaded to a HIS-Select™ Cartridge (Sigma P6611) equili-
brated with buffer A. After extensive washing, the protein was eluted
with 50 mM Na-acetate buffer pH 4.5 containing 150 mM NaCl. The
eluted fractions were concentrated with a YM10 Diaflo membrane
(Amicon, Danvers, MA), dialyzed overnight in 50 mM NH4-acetate,
lyophilized and stored at − 80 °C.
The purity of proteins was analyzed by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE).
Protein concentrations of the TPPP/p25 variants were determined
on the basis of the absorbance at 280 nm using the extinction co-
efficients evaluated by ProtParam [39], 10,095 M− 1 *cm− 1 for full
length TPPP/p25, ML, SL, DL, LL, TL, CL; 5625 M− 1 *cm− 1 for DT,
DTML, DTSL, DTDL, rfr-1, and 4470 M− 1 *cm− 1 for rfr-3, respec-
tively. Since rfr-2 does not contain any Trp, Tyr or Phe, its concentra-
tion was determined by the Bradford method [40].
2.5. Tubulin and SYN preparation
Tubulin was prepared from bovine brain according to the method
of Na and Timasheff [41]. Human recombinant SYN was prepared as
described previously [42]. SYN concentration was determined from
the absorbance at 280 nm using an extinction coefficient of
5960 M−1 *cm− 1.
2.6. Circular dichroism (CD) spectroscopy
CD measurements were performed on Jasco J-720 spectropo-
larimeter at 20 nm/min scan rate, 8 s time constant and 1 nm step size
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in 10 mM phosphate buffer, pH 7.2 at room temperature. The path
length was 0.1 cm. Protein concentrations were 4–15 μM for TPPP/
p25 forms, 4 μM for SYN and 1 μM for tubulin. The mixtures were in-
cubated for 10 min before recording the spectra. The difference spec-
trum was obtained by subtracting the spectra of the individual pro-
teins from that of the mixture of two proteins (tubulin and the vari-
ous TPPP/p25 forms). Mean molar ellipticity per residue (MRE) in de-
grees square centimeter per decimole was calculated according to the
following equation: MRE = Θm/(10*n*c*l), where Θm is the measured
ellipticity (millidegrees), n is the number of amino acid residues in a
protein, c (mol) is the concentration and l (cm) is the path length of the
cell. Data from three–five independent measurements were averaged.
2.7. 8-Anilinonaphthalene-1-sulfonic acid (ANS) fluorescence
The fluorescence measurements were performed in 50 mM Tris
buffer, pH 7.5 at 25 °C using a Jobin Yvon Fluoromax-3 spectroflu-
orometer (Jobin Yvon Horiba, Longiumeau, France). A quartz cu-
vette of 1 cm optical path length and freshly prepared 10 mM ANS
stock solution made with ultrapure water were used for each exper-
iment. The fluorophore was excited at 380 nm, emission was mon-
itored from 400 to 600 nm, the slits were adjusted to 2 nm as de-
scribed in [43]. All measurements were done in triplicate. Data were
processed using DataMax software. A blank spectrum without pro-
tein was recorded before addition of the wild type or truncated TPPP/
p25 forms and ZnCl2. The concentration of ANS, TPPP/p25 forms and
ZnCl2 was 50 μM, 2.5 μM and 20 μM, respectively. Three–nine inde-
pendent measurements were carried out.
2.8. Enzyme-linked immunosorbent assay (ELISA)
The plate was coated with 5 μg/ml (50 μl/well) SYN in phosphate
buffered saline as described previously [35]. Briefly, after blocking
the wells with bovine serum albumin (BSA), the immobilized pro-
teins were incubated with serial dilutions of wild type or mutant
TPPP/p25 forms followed by the addition of TPPP/p25 antibody [16]
and the corresponding peroxidase conjugated secondary IgG. In an-
other experimental setup, the plate was coated with 5 μg/ml (50 μl/
well) wild type or mutant TPPP/p25 forms, and after blocking the
wells with BSA the immobilized proteins were incubated with serial
dilutions of polyclonal TPPP/p25 antibody [16] or with serial dilu-
tions of tubulin followed by the addition of tubulin antibody (Sigma
T9026) and the corresponding peroxidase conjugated secondary IgG.
The bound antibodies were detected using o-phenylenediamine as sub-
strate. The reaction was stopped after 10 min with 1 M H2SO4, and the
absorbance was read at 490 nm with an EnSpire Multimode Reader
(Perkin Elmer). The binding constants (Kd) were evaluated from the
saturation curves by non-linear curve fitting assuming single binding
site hyperbola model using the Origin 8.0 software.
In the case of the competitive ELISA, the plate was coated with
5 μg/ml (50 μl/well) TPPP/p25 in phosphate buffered saline. After
blocking the wells with BSA, 0.5 μM SYN preincubated for 30 min in
room temperature with 2.5 μM or serial dilutions of TPPP/p25 forms/
peptides was added to the immobilized TPPP/p25. The bound SYN
was quantified by monoclonal SYN antibody as described above.
2.9. Turbidity measurements
The assembly of tubulin (6 μM) was assessed in polymerization
buffer (50 mM 2-(N-morpholino)ethanesulfonic acid buffer pH 6.6
containing 100 mM KCl, 1 mM dithioerythritol, 1 mM MgCl2 and
1 mM ethylene glycol tetraacetic acid ) at 37 °C. The tubulin poly-
merization into microtubules was induced by the addition of 3 μM of
the different TPPP/p25 forms. The optical density was monitored at
350 nm by a Cary 100 spectrophotometer (Varian).
2.10. Multinuclear nuclear magnetic resonance (NMR)
Uniformly labeled (15N- and/or 13C–label) DT protein was pro-
duced as described previously using M9 minimal medium containing
15NH4Cl and
13C-glucose as sole nitrogen and carbon sources, respec-
tively [10].
For backbone assignment and structural characterization of human
N- and C-terminal free TPPP/p25 protein 1D, 2D and 3D NMR ex-
periments were carried out at 288 K such as 1H-15N-HSQC (8 tran-
sients collected using 118 ppm offset; 26 ppm spectral window and
incremented in 512 points in the indirect dimension), 1H-13C-HSQC
(16 transients with 40 ppm offset and 64 ppm spectral window incre-
mented in 256 points in F1), HNCA, HNCOCA (for both indirect di-
mension: 8 transients with 50 ppm offset and 64 ppm window for 13C
and incremented in 64 × 128 points), HNCACB (16 transients col-
lected with 40 ppm offset and 64 ppm spectral width for 13C and in-
cremented in 64 × 128 points), CCCONH (16 transients collected at
40 ppm offset with 64 ppm spectral window incremented in 64 × 128
points in the indirect dimensions).
Titration with SYN was carried out by recording a series of
1H-15N-HSQC spectra at increasing SYN concentration added to the
800 μM DT sample (8 scans are incremented in 512 points with
26 ppm spectral width at 117 ppm offset), final concentration of DT
and SYN was 381 and 327 μM, respectively. SYN perturbation was
evaluated by comparing both the 1H and 15N chemical shifts of TPPP/
p25 corresponding to 82.5% titration with that of the free protein and
calculated as follows: perturbation = ((Δδ15N/6.51)2 + (Δδ1H/1)2)1/2.
2.11. Computational analysis of intrinsic disorder propensity of wild
type and mutant forms of human TPPP/p25
We evaluated intrinsic disorder propensity of various TPPP/p25
variants by so-called binary predictors, charge-hydropathy plot
(CH-plot) and cumulative distribution function plot (CDF-plot). The
CH-plot of a particular sequence is a linear disorder classifier that
discriminates proteins with substantial amounts of extended disorder
from proteins with globular conformations [44,45]. A CH-plot shows
results from a binary disorder predictor and represents an input pro-
tein as a 2D graph, in which the mean Kate-Doolittle hydrophobicity
and the mean absolute net charge are projected onto the X- and Y-co-
ordinates, respectively. In the corresponding CH-plot, fully structured
proteins and fully disordered proteins can be separated by a boundary
line. All proteins located above this boundary line are highly likely
to be extended, while proteins located below this line are likely to
be compact [44,45]. CDF-plot is a cumulated histogram of disordered
residues at various disordered scores [45,46]. The cumulated his-
togram for structured proteins increases faster in the range of smaller
disordered scores and then goes flat at larger disordered scores, while
the cumulated histogram for disordered proteins increases slightly in
the range of lower disordered score but significantly at higher disor-
dered scores. There is a boundary line in the CDF-plot, and the posi-
tion of a CDF line of a given protein relative to this boundary defines
the disorder status of this protein [44].
UN
CO
RR
EC
TE
D
PR
OO
F
BBA - Molecular Basis of Disease xxx (2016) xxx-xxx 5
2.12. Cell culture, transfection and manipulation
HeLa cells (ATCC® CCL-2™, American Type Culture Collec-
tion) were grown in Dulbecco's modified eagle medium supplemented
with 10% fetal calf serum and 100 μg/ml kanamycin in a humidi-
fied incubator at 37 °C with 5% CO2. Cells were routinely checked
for mycoplasma contamination by microscopy using 4,6-di-
amidino-2-phenylindole (DAPI) staining. Cells were grown on
12-mm-diameter glass coverslips for microscopic analysis. For the
co-localization studies HeLa cells were transfected with EGFP-TPPP/
p25 or EGFP-CORE constructs, then the cells were stained with a
monoclonal antibody against α-tubulin (Sigma T9026); the full length
and the truncated TPPP/p25, as well as the microtubule network, were
visualized by fluorescence microscopy. Images of the mounted sam-
ples were acquired on a Leica DM IL 500 microscope equipped with
Leica DFC 395 FX camera and HBO 100w lamp. The equipment soft-
ware was Leica Application Suite 4.4.0. Chroma UV filter set (No.
C40888), Chroma 41028 HQ NB GFP filter set (No. C21116) and Le-
ica filter N2.1 (No. 513832) was used for DAPI, EGFP and Alexa 546
signal acquisition, respectively, using a HCX FL Fluotar 40 ×/0.75
(dry) objective.
For the evaluation of the BiFC signal, HeLa cells were transfected
with the mVenus BiFC constructs of TPPP/p25 and SYN (0.3 μg of
each plasmid) using Turbofect (Invitrogen) transfection reagent ac-
cording to the manufacture's protocol. 0,3 μg competitor unlabeled
TPPP/p25 plasmid was co-transfected with mVenus BiFC constructs
where it mentioned. Nuclei were counterstained with DAPI. Images of
the mounted samples were acquired on a Leica DM IL 500 microscope
as above. Chroma UV filter set (No. C40888) and Chroma 41028 Y
GFP filter set (No. C2117) was used for DAPI and Venus signal ac-
quisition, respectively.
For image analysis, the pictures were taken under constant expo-
sure parameters. The determination of the BiFC signal (green fluo-
rescence) was performed by using the Analyze, Measure option of
the National Institutes of Health ImageJ software using the original
grayscale pictures. The whole territory of each cell was outlined by the
Freehand Line tool and integrated pixel densities calculated by multi-
plying the area of each cell with the corresponding average pixel in-
tensity subtracting the background.
2.13. Statistical analysis
The error bars represent the standard deviation (SD). Comparisons
were performed using the unpaired Student's t-test and values were
considered to be significant if the calculated p value was < 0.05 (*).
3. Results
3.1. Generation of deletion mutants of TPPP/p25
Earlier we showed that the 147KAPIISGVTK156 segment of the
flexible CORE region of TPPP/p25 is involved in the formation of the
pathological TPPP/p25-SYN complex, while the 178–187 segment of
the C-terminus takes part in the formation of the physiological TPPP/
p25-tubulin/microtubule complex [35]. Deletion and/or truncated vari-
ants and fragments of the human TPPP/p25 were produced by re-
combinant techniques as described in the Materials and Methods and
used for structural and functional studies. The deletions analyzed in
this study were focused on the functional regions of TPPP/p25. These
TPPP/p25 forms are schematically shown in Fig. 1 and are described
in Table 2.
Fig. 1. Scheme of the different TPPP/p25 forms.
3.2. Effect of the TPPP/p25 deletions on the interaction with tubulin/
microtubules
We reported that the deletion of the unstructured N- and C-ter-
mini of TPPP/p25 (DT) resulted in significant decrease in the tubulin
polymerization promoting activity of this protein [35], and a specific
ELISA experiment suggested the role of the 178–187 segment (TL) in
the binding of TPPP/p25 to tubulin [35].
Now we performed in vitro studies with deletion mutants and frag-
ments of TPPP/p25 related to its C-terminal region, TL, rfr-2 and
rfr-3 (see Fig. 1). Previously we showed that the interaction of the
full length TPPP/p25 (FL) with tubulin produced a characteristic dif-
ference CD spectrum (Fig. 2A) that was significantly reduced due to
the truncation of the unstructured N- and C-termini (DT) [35]. Sim-
ilar set of experiments was carried out with the TL deletion mutant
(Δ178–187) and the rfr-2 and rfr-3 fragments, which include distinct
segments of the C-terminal region of TPPP/p25 (cf. Fig. 1). As illus-
trated in Fig. 2B, in the case of the fragments virtually no CD differ-
ence signals were evolved, whereas in the case of TL a reduced dif-
ference spectrum was observed. ELISA experiments with the C-termi-
nal mutants are shown in Fig. 2C. While the TL deletion mutant be-
haved similarly as the full-length TPPP/p25 (FL), the two C-terminal
fragments of this protein displayed significantly reduced (rfr-3) or no
(rfr-2) binding capacity toward tubulin. The turbidity measurements
(Fig. 2D) underlined the results of the binding studies, namely that
the TL deletion mutant maintained the tubulin polymerization promot-
ing activity, whereas the fragments failed to induce tubulin polymer-
ization. Finally, experiments carried out with a mutant of the CORE
region (SL, see Fig. 1) involved in the formation of the pathologi-
cal TPPP/p25-SYN complex [35], proved that the deletion of this re-
gion caused only modest, if any, reduction in the association of the
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Fig. 2. Interaction of tubulin with TPPP/p25 deletion mutants affecting the C-terminal region. (A–B) Difference CD spectra of TPPP/p25 forms and tubulin. Difference ellipticity
was calculated by subtracting the ellipticities of tubulin and the TPPP/p25 forms from that measured with their mixtures. The concentration of tubulin, TPPP/p25, TL, rfr-2 and rfr-3
was 1, 5, 5, 15 and 10 μM, respectively. (A) Spectrum of FL (solid line) and tubulin (dashed line), complex spectrum (dotted line), difference spectrum (bold line), average of three
independent experiments. (B) Difference spectrum of FL (bold line), TL (solid line), rfr-2 (dashed line), rfr-3 (dotted line), average of three independent experiments. (C) ELISA
experiment. The plate was coated with the various TPPP/p25 forms, then it was incubated with tubulin at different concentrations. The bound tubulin was detected by tubulin antibody
as described in the Materials and Methods. FL (●), TL (○), rfr-2 (∆), rfr-3 (▲). The results are presented as means ± the standard deviation (SD). The binding affinities of the
distinct TPPP/p25 forms to tubulin evaluated by curve fitting assuming simple hyperbolic saturation were found to be 16.4 ± 1.4 (FL, n = 11), 29.8 ± 2.7 (TL, n = 3), and 97.0 ± 29.9
(rfr-3, n = 4) nM, respectively. For rfr-2, n = 3. (D) The tubulin polymerization promoting potency of the TPPP/p25 forms followed by turbidimetry. The polymerization of 6 μM
tubulin to microtubules was induced by the addition of 3 μM of each TPPP/p25 form. A representative experiment is shown, n = 3–8.
TPPP/p25 with tubulin (Fig. 2D). Therefore, the physiological inter-
face seems to be, indeed, distinct from the pathological one within the
CORE region.
3.3. NMR spectroscopy of the SYN binding to the CORE region of
TPPP/p25
Both the co-enrichment and the co-localization of TPPP/p25 and
SYN were detected in brain inclusions of patients suffering from
Parkinson's disease and multiple system atrophy [16]; the direct asso-
ciations of the two disordered proteins were characterized at molecular
and cellular levels [35,36]. In addition, the CORE region (45–174 aa)
of TPPP/p25, specifically the 147–156 aa segment of this protein, was
suggested by ELISA experiments to be localized at the interface in the
TPPP/p25-SYN pathological complex [35]. However, the synthesized
147–156 aa peptide resulted in only partial inhibition of its assembly.
In order to assign the amino acid residues involved in the formation
of the pathological complex, multinuclear NMR studies of the 15N-la-
beled CORE segment were performed without and with SYN.
A number of resonance frequencies of the 1H-15N HSQC spectra
were sharp and poorly dispersed in the amide region (Fig. 3A), indi
cating the intrinsically disordered character of these residues. Fur-
thermore, these peaks predominantly fell in the narrow region of
7.8–8.6 ppm 1H, which is typical for the highly flexible proteins, in-
dicating their ability to fluctuate among a multitude of conformational
states, therefore, lacking a well-defined single time-average structure
[47,48]. The addition of SYN to the 15N-labeled double truncated
TPPP/p25 apparently did not cause global structural changes of the
protein. However, the addition of SYN led to significant changes in
the chemical shifts of amides of some TPPP/p25 residues, indicating
that there was an alteration of the chemical environment around these
TPPP/p25 groups involved in the direct contact with SYN. Larger per-
turbation than the arbitrarily defined cut-off signal (0.017 ppm) was
detected for the assigned residues within the 110–122 aa region, at the
residues 110–111, 114, 117, 121–122 of the CORE segments that cor-
responds to the 151–164 region of the full length protein (Fig. 3B).
Furthermore, a new segment, 18–21 (59–62 aa in the full length) was
identified as another SYN binding region. These findings indicate the
complex nature of the interaction mode of the truncated TPPP/p25
with SYN. Therefore, it can be concluded, that at least two separated
domains of the CORE segment of TPPP/p25 could be involved in the
SYN binding.
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Fig. 3. Multinuclear NMR spectroscopy of the CORE TPPP/p25 with added SYN. (A) Backbone H N cross-peaks. (B) Residues 18–21, 58, 110–111, 114, 117, 121–122 aa
display larger than 0.017 ppm threshold shift due to the addition of SYN. Final concentration of DT and SYN was 381 and 327 μM, respectively.
3.4. Effect of the deletions in the CORE segment of TPPP/p25 on its
association with SYN
Previously we suggested the involvement of the 147–156 segment
of the CORE region in the SYN binding [35]. Now the multinuclear
NMR analysis underlined this observation and suggested the involve-
ment of the 59–62 segment (ML) in the constitution of the interface of
the TPPP/p25-SYN complex (see Fig. 3). Accordingly, double dele-
tion mutants of the full length TPPP/p25 (DL) and the CORE vari-
ant (DTDL) were designed, expressed, isolated, and their interactions
with SYN were characterized by ELISA as follows: SYN was immo-
bilized on ELISA plate followed by the addition of TPPP/p25 variants
at different concentrations. Complex formation was detected by the
TPPP/p25 antibody as described in the Materials and Methods. Fig.
4A illustrates that the polyclonal TPPP/p25 antiserum recognized the
mutant TPPP/p25 species, and could be used for quantification of the
hetero-association between TPPP/p25 and SYN.
The double deletion mutant of the full length TPPP/p25 (DL) dis-
played decreased, but comparable binding affinity to the SYN as the
wild type protein (FL) (Fig. 4B). However, the double deletion mutant
of the CORE variant (DTDL) virtually failed to associate to SYN (Fig.
4B); this termini-free form, the CORE with double deletion is the sin-
gle variant of TPPP/p25 mutants that did not bind to SYN. This find-
ing revealed the contribution of the unstructured tails of TPPP/p25 to
form the pathological complex.
In fact, we tested several single deletion mutants of both the FL
and DT (CORE) variants such as ML, SL, LL, CL, DTML and DTSL
(cf. Table 2 and Fig. 1 for the identification of the TPPP/p25 vari-
ants). As shown in Fig. 4B, no or limited reduction in the SYN binding
was detected. It is also worth mentioning that the fragments involving
the 147–156 segment (rfr-2 and rfr-3) failed to associate to SYN (Fig.
4B). These results highlighted the mutual association of the distinct
TPPP/p25 segments to SYN.
The binding affinities of the deletion/truncated TPPP/p25 mutants
to SYN were evaluated by curve fitting assuming simple hyperbolic
saturation. Analysis of these data revealed that the various deletion
mutants can be arranged in the following order according to their
SYN binding affinities:
Rather interestingly, we noticed that the association of the two dis-
ordered proteins, TPPP/p25 and SYN, did not result in the formation
of a difference CD spectrum (Fig. 4C) in spite of their hetero-asso-
ciation, while in the case of the interaction of the disordered TPPP/
p25 and the globular tubulin extensive spectral changes as difference
ellipticity spectrum could be detected (cf. Fig. 2A). These findings,
where the disordered TPPP/p25 obviously possesses distinct confor-
mational states by interacting with SYN or tubulin, are indicative of
the chameleon nature of TPPP/p25 as well.
3.5. Deletion-derived conformational changes of TPPP/p25
Next, the conformational properties of the deletion and/or trun-
cated mutants and fragments of TPPP/p25 were characterized as com-
pared with the full length protein (cf. Fig. 1). To this end, we utilized
both experimental and computational approaches and analyzed vari-
ous TPPP/p25 constructs by CD and ANS spectroscopy as well as by
various prediction software products developed for characterization of
IDPs.
TPPP/p25 displayed a CD spectrum with high random coil con-
tent characteristic for the highly disordered proteins [7,49]. As shown
in Fig. 5A, in the case of the full length TPPP/p25 (FL) and its dele-
tion mutants (ML, SL, DL, LL, TL) the minimum is at 205 nm in-
dependently of the nature of the deletions. However, the truncation
of the disordered N- and C-terminal tails (DT) produced a partially
folded protein as evidenced by the altered minimum and the sig-
nificant changes in the ratio of the ellipticities at the minimum and
222 nm. This feature seemed to be maintained in the case of the dou-
ble truncated double deletion form (DTDL) that appeared as an inac-
tive variant with respect to SYN binding. In contrast to the truncation
mutants (DT without and with deletions), the CD spectra of the frag-
ments (rfr-2 and rfr-3) of TPPP/p25 displayed exclusively random coil
structure corresponding to an unfolded polypeptide chain (Fig. 5A).
Since the binding of ANS to the hydrophobic regions of proteins
is coupled with an enhanced fluorescence intensity and a pronounced
blue shift of the fluorescence maximum, this technique is a unique
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Fig. 4. Interaction of SYN with TPPP/p25 deletion mutants affecting the CORE re-
gion. (A) Polyclonal TPPP/p25 antiserum recognizes the various mutant forms as de-
tected by ELISA. The plate was coated with the different TPPP/p25 species, then
polyclonal TPPP/p25 antiserum was added at saturation value. The results are pre-
sented as means ± the standard deviation (SD). The values were normalized with re-
spect to that measured for the FL. (B) Binding of SYN to the various TPPP/p25
mutants determined by ELISA experiment. The plate was coated with SYN, then
it was incubated with the various TPPP/p25 forms at different concentrations. The
binding affinities of the distinct TPPP/p25 forms to SYN evaluated by curve fit-
ting assuming simple hyperbolic saturation were found to be 48.9 ± 6.7 (FL, n = 7),
51.3 ± 2.7 (ML, n = 4), 194 ± 22 (SL, n = 4), 99.5 ± 12 (DL, n = 3), 77.3 ± 13 (LL,
n = 3), 84.3 ± 6.2 (CL, n = 2), 499 ± 44 (DT, n = 6), 1865 ± 217 (DTML, n = 4) and
2392 ± 209 (DTSL, n = 4) nM, respectively. The results are presented as means ± the
standard deviation (SD). For rfr-2 and rfr-3, n = 2. (C) Difference CD spectrum of
TPPP/p25 form and SYN. Differ
ence ellipticity was calculated by subtracting the ellipticities of SYN and TPPP/p25
from that measured with their mixtures. The concentration of SYN and TPPP/p25 was 4
and 4 μM, respectively. Spectrum of FL (dashed line) and SYN (solid line), difference
spectrum (dotted line), average of three independent experiments.
Fig. 5. Effect of the different mutations on the structural characteristics of TPPP/p25.
(A) Far-UV CD spectra of the various TPPP/p25 forms. Average of three–five indepen-
dent experiments (B) ANS fluorescence spectroscopy. Representative emission spectra
are shown. The concentration of ANS and protein was 50 μM and 2.5 μM, respectively;
n = 3–9 experiments. (C). Normalized far-UV CD spectra of TPPP/p25 and rfr-1 species
without and with 200 μM zinc. FL (bold line) with zinc (solid line), rfr-1 (dashed line)
with zinc (dotted line), average of three independent experiments.
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test for identification of the molten globule state [50,51]. Previously,
we detected these effects upon addition of ANS to the full-length
TPPP/p25 as well. We reported the suitability of the ANS assay
for the characterization of the effect of the bivalent zinc ion on the
protein [43], because TPPP/p25 contains a zinc-finger region
(His61(X)10His
72(X)7Cys
80(X)2Cys
83) responsible for the specific
binding of this cation [43]. Now we tested the effect of the various
mutants and fragments on the ability of TPPP/p25 to undergo zinc-in-
duced local structural alterations. Note that the His and Cys residues
of the zinc-finger motif are not affected by the deletions, except in
the cases of ML and DL, where His61 is missing. Deletions of one or
more segments with different lengths produced relatively minor de-
crease in the ANS signal; significant change appeared in the case of
the SL (Δ147–156) and the double truncated (CORE) forms (Fig. 5B,
Additional file 1). The addition of zinc ion significantly increased the
ANS fluorescence intensity in all truncated forms as well as in the
full length TPPP/p25 except in the variants (ML, DL, DTML, DTDL)
where His61 was deleted. On the basis of ANS data the hydrophobicity
of the TPPP/p25 variants is the following: (Fig. 5B, Additional file 1):
The finding that the zinc-induced structural changes were restricted
to the zinc-finger region is supported by the far-UV CD data (Fig. 5C).
We found that the 43–90 fragment of TPPP/p25 (rfr-1) with the zinc
finger region displayed similar structural change by the addition of
zinc as the full length TPPP/p25 indicating that a well-defined binding
domain can be maintained in a well-defined segment/fragment of the
disordered protein, no “chameleon effect” has to be assumed to eluci-
date the phenomenon.
Next, we conducted a multiparametric computational analysis of
various deletion and truncation mutants of TPPP/p25 in order to un-
derstand how sequence alterations would affect intrinsic disorder
propensity of this protein. Results of the evaluation of per-residue
intrinsic disorder predisposition of various TPPP/p25 variants by a
set of the predictors of PONDR family and the effect of mutations
and truncations on the disorder-based interactivity of this protein are
summarized in Additional file 2. Although we used several unrelated
per-residue disorder predictors sensitive to different sequence attrib-
utes, the outputs of these different computational tools are typically
in agreement with each other (see Additional files 2, 3). Furthermore,
these computational analyses generally agreed with the experimental
data and clearly showed that the full length TPPP/p25 is a highly dis-
ordered protein. Deletion mutations did not have a significant effect
on the disorder status of this protein, whereas truncation of its N- and
C-termini (as well as the subsequent deletions within this truncated
form) made TPPP/p25 more ordered [35].
We also looked at the intrinsic disorder propensities of the wild
type human TPPP/p25 and its variants using binary disorder predic-
tors that classify the entire protein as ordered or disordered as a whole,
and the results of this analysis are shown in Fig. 6. CDF analysis is
shown in Fig. 6A. It summarizes the per-residue disorder predictions
by plotting PONDR scores against their cumulative frequency, which
allows ordered and disordered proteins to be distinguished on the ba-
sis of the distribution of prediction scores [44]. At any given point on
the CDF curve, the ordinate gives the proportion of residues with a
PONDR score less than or equal to the abscissa. The optimal bound-
ary that provided the most accurate order-disorder classification was
shown to represent seven points located in the 12th through 18th bins
[44]. Thus, for CDF analysis, order-disorder classification is based
on whether a CDF curve of a given protein is above or below a ma-
jority of boundary points. Fig. 6A shows that the full-length TPPP/
p25 and all its deletion mutants were predicted to be disordered, since
their CDF curves were located below the boundary. On the other hand,
CDF curves corresponding to the truncated TPPP/p25 and its deletion
variants were all located in close vicinity to the boundary line, sug-
gesting that the overall disorder status of these forms of TPPP/p25 is
“undecided”.
Fig. 6B represents a CH-plot, where the absolute mean net charges
of proteins (R) are plotted against their mean hydropathy (H) and
which shows that ordered and disordered proteins tend to occupy two
different areas within the charge-hydrophobicity phase space, being
separated by an estimated boundary line, R = 2.785*H - 1.151 [45]. It
is known that the CH-plot is able to discriminate proteins with sub-
stantial amounts of extended disorder (random coils and pre-molten
globules, which are located above the boundary) from proteins with
globular conformations (molten globule-like and ordered globular
proteins, which are positioned below the boundary) based on charge
and hydropathy of their sequences [44]. Fig. 6B shows that the
full-length TPPP/p25 protein and its deletion mutants (except to TL,
Δ178–187) were located above the boundary separating compact pro-
teins and extended disordered proteins and were, therefore, predicted
to be disordered. On the other hand, TL variant, truncated TPPP/p25,
and all its deletion variants were predicted to be compact, being lo-
cated below the boundary.
Concluding, according to the results of CDF-plot (Fig. 6A) and
CH-plot analysis (Fig. 6B), the full-length TPPP/p25 protein and its
deletion mutants were all predicted to be disordered as a whole. On
the other hand, CORE of TPPP/p25 and its deletion mutants were pre-
dicted to be compact proteins with “undecided” disorder status.
3.6. Chameleon nature and druggability of the disordered TPPP/p25
The data obtained for the deletion mutants and fragments of TPPP/
p25 and the interactions of these variants with the physiological (tubu-
lin) and pathological (SYN) partners are summarized in Table 3.
On the basis of these data it can be concluded that the deletions
of various central regions virtually did not affect the interactions of
TPPP/p25 with either tubulin or SYN, whereas the truncation of the
unstructured termini did have a strong influence on the binding and
function of this protein to tubulin and SYN (cf. Fig. 2C and D). Our
studies clearly indicated that the deletions of internal segments of the
full length TPPP/p25 involved in the hetero-associations could be re-
placed by other segments or conformations adapted by the mutations
themselves and/or due to the association with SYN. This is a plausi-
ble explanation for the interpretation of the binding and functional re
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Fig. 6. Evaluation of disorder propensities of TPPP/p25 and its variants by binary disorder predictors. (A) CDF analysis of whole protein order and disorder. CDF curves for TPPP/25
and its various forms are shown as colored lines, and the order-disorder boundary is shown as a black line. (B) CH-plot analysis of whole protein order and disorder. Data for TPPP/
25 and its various forms are shown as differently colored symbols. Data for compact ordered proteins and known extended disordered proteins are shown as light-blue diamonds and
light-pink circles, respectively. The order-disorder boundary is shown as a black line.
sults obtained with mutants; however, one can suggest other ones to be
considered. Given that both proteins are intrinsically disordered, the
proteins could tangle/slide on each other displaying interactions. The
interaction between the positively and negatively charged TPPP/p25
and SYN, respectively, indeed, is not necessarily conformational spe-
cific, it could be driven by side chain salt bridges in spite of the fact
that all binding experiments were performed at physiological salt con-
centration. Therefore, in the case of the TPPP/p25-SYN complex more
than one segment of these disordered proteins could be involved in the
construction of interface of the assembled proteins that cooperatively
can affect the specificity and/or affinity the hetero-association.
3.7. Validation of the interface for drug targeting
To validate the segment of the full-length TPPP/p25 relevant at
pathological conditions as a potential drug target, competitive ELISA
experiments were carried out. This in vitro assay with human recom-
binant proteins, TPPP/p25 and SYN, is a well-established approach
for screening interaction inhibitors. We used recombinant and synthe-
sized fragments of TPPP/p25 that are expected to function according
to their direct binding potency.
In the competitive ELISA assay, the TPPP/p25 variants used as
competitors were premixed with SYN at constant concentration, then
added to the full-length TPPP/p25 immobilized on the ELISA plate.
The inhibitory effect of the competitors on the interaction of SYN with
the immobilized TPPP/p25 was detected by a SYN antibody as de-
scribed in the Materials and Methods. As shown in Fig. 7A, mutants
of the full length TPPP/p25 (FL) displayed similar inhibitory potency
as the control, while the double truncated form (DT) and its mutants,
specifically the one with the deletions of the 59–62 and 147–156 seg-
ments (DTDL), showed very low inhibitory activity.
Fig. 7B illustrates the concentration-dependent inhibitory effects of
the double truncated forms (DT, DTDL) and fragments. While 10 μM
DT produced 80% inhibition, DTDL displayed only 20% inhibitory
activity indicating that multiple deletions (terminals and within the
CORE segment) are needed to eliminate the interaction of TPPP/p25
with SYN.
The inhibitory (competitive) potency of synthetized peptides of
TPPP/p25, BF181, BF182 and BF183 (see Fig. 1) used previously in
interaction studies [35] were also tested in a similar set of ELISA ex-
periments. Fig. 7B shows that only the BF182 peptide corresponding
to the 147–156 segment inhibited significantly the binding of SYN to
the full-length TPPP/p25. These results further corroborated that the
10 aa segment of TPPP/p25 within the flexible CORE region plays
a role in the formation of the pathological TPPP/p25-SYN complex,
in addition that the competitive ELISA is a simple, powerful assay to
screen potential anti-Parkinson drugs.
UN
CO
RR
EC
TE
D
PR
OO
F
BBA - Molecular Basis of Disease xxx (2016) xxx-xxx 11
Table 3
Structural and functional features of the deletion mutant and fragments of TPPP/p25.
FL ML SL DL LL TL CL
Sequence 1–219 1–58, 63–219 1–146, 157–219 1–58, 63–146, 157–219 1–141, 162–219 1–177, 188–219 1–111, 145–219
Characteristics
CH-plot prediction Disordered Disordered Disordered Disordered Disordered Ambiguous Disordered
CD spectrum Random coil Random coil Random coil Random coil Random coil Random coil
CD + zinc Yes
ANS Yes Yes Reduced Yes Yes Yes
ANS + zinc Increase Slight increase Increase Slight increase Slight Increase Increase
pAb Yes Yes Yes Yes Yes Yes Yes
Interaction with tubulin/MT
ELISA Yes Yes Yes Yes Yes Yes Yes
CD Yes Yes Yes Reduced Yes Reduced
Turbidity Yes Yes Yes Yes Yes Yes
Interaction with SYN
ELISA Yes Yes Yes Yes Yes Yes
competitive ELISA Yes Yes Yes Yes Yes
DT DTML DTSL DTDL
Sequence 1–2, 44–174 1–2, 44–58, 63–174 1–2, 44–146, 157–174 1–2, 44–58, 63–146, 157–174
Characteristics
CH-plot prediction Compact Compact Compact Compact
CD spectrum Partially folded Partially folded Partially folded Partially folded
CD + zinc
ANS Reduced Yes Reduced Reduced
ANS + zinc Increase Slight increase Increase Slight increase
pAb Yes Yes Yes Yes
Interaction with tubulin/MT
ELISA
CD No [35]
Turbidity No [35]
Interaction with SYN
ELISA Reduced Reduced Reduced No
Competitive ELISA Reduced Reduced Reduced No
rfr-1 rfr-2 rfr-3
Sequence 43–90 142–187 142–177, 188–219
Characteristics
CH-plot prediction
CD spectrum Random coil Unfolded Unfolded
CD + zinc Yes
ANS No No
ANS + zinc No No
pAb Yes Yes
Interaction with tubulin/MT
ELISA No Reduced
CD No No
Turbidity No No
Interaction with SYN
ELISA No No
Competitive ELISA
3.8. Dynamic association of TPPP/p25 and SYN in HeLa cells
We applied BiFC technology using mVenus vectors (VN-SYN and
VC-TPPP/p25, Fig. 8A) to verify the dynamic hetero-association of
the wild type TPPP/p25 and SYN as relevant pathological forms in
HeLa cells.
Previously we reported that in transiently transfected HeLa cells
the full length (FL) EGFP-TPPP/p25 were aligned along the micro-
tubule network at relatively low expression level (Fig. 8B, panel a),
while the double truncated TPPP/p25 (DT) accordingly to the in vitro
experiments distributed within the cytosol (Fig. 8B, panel b) [35].
Applying the BiFC technology now we provided evidence for the
in vivo hetero-association of TPPP/p25 and SYN in HeLa cells, in ad-
dition we showed that the pathological complex appeared to be co-lo-
calized on the microtubule network (Fig. 8B, panel c). To establish
the dynamic nature of the hetero-association of the two disordered
proteins as well as the availability of this technology for drug test-
ing, unlabeled TPPP/p25 as competitor was also expressed in the
HeLa cells (Fig. 8B, panel d). As visualized in the immunofluores-
cence images, the “competitor” reduced the formation of the TPPP/
p25-SYN-derived assembly of the mVenus pair as indicated by the
quantification of the green fluorescence signal (Fig. 8C). In addition,
the expression of the unlabeled TPPP/p25 (competitor) resulted in
the release of the mVenus complex from the microtubule network as
well (Fig. 8B, panel d). Indeed, it displayed homogeneous distribution
within the cytosol similarly to that obtained with the CORE segment
of TPPP/p25 which associates poorly, if at all, to the microtubule net-
work [35]. The results at cellular level underlined the data obtained
with human recombinant proteins in vitro, and provided a valuable as-
say for testing potential anti-Parkinson drugs at cellular level.
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Fig. 7. Effect of the various TPPP/p25 mutants and decapeptides on the SYN-TPPP/p25 interaction determined by competitive ELISA. The plate was coated with TPPP/p25, then
0.5 μM SYN preincubated for 30 min in room temperature with 2.5 μM (A) or serial dilutions of TPPP/p25 forms/peptides (B) was added to the immobilized TPPP/p25. The bound
SYN was quantified by monoclonal SYN antibody. The ELISA data were normalized with respect to SYN at 0.5 μM without TPPP/p25 mutants or peptides. (A) *Significant differ-
ence with respect to SYN with FL, p = 2.01E-3 for DT, p = 8.34E-3 for DTML, p = 8.17E-3 for DTSL and p = 5.64E-8 for DTDL. #Significant difference with respect to SYN with
DT, p = 1.42E-4. n = 11 for SYN, n = 9 for FL, n = 3 for ML, n = 4 for SL, n = 6 for DL, n = 5 for LL, n = 8 for DT, n = 5 for DTML, n = 3 for DTSL, and n = 10 for DTDL, respec-
tively. (B) DL (Δ), DTDL (▲), BF182 (○), BF181 (●), BF183 (♦). n = 3 for DT, and n = 2 for DTDL, BF181, BF182 and BF183, respectively. (A–B) The results are presented as
means ± the standard deviation (SD).
Fig. 8. Dynamic association of TPPP/p25 with SYN on the microtubule network in living HeLa cells as visualized by BiFC technology. (A) Scheme of BiFC constructs for gener-
ation of BiFC signal (green) by co-transfection TPPP/p25 and SYN fused to mVenus BiFC constructs (a generous gift of Prof. Péter Várnai; Physiology Department, Semmelweis
University, Budapest). (B): (a) Localization of EGFP-TPPP/p25 on the microtubule network (red). (b) Distribution of the EGFP-CORE segment within the cytosol. (c) Alignment of
the associated mVN-SYN and VC-TPPP/p25 (green). (d) Effect of the unlabeled TPPP/p25 expressed ectopically on the localization of TPPP/p25-SYN interaction-derived mVenus
signal. Bar: 10 μm. (C) Quantification of the BiFC signal by detecting the individual cell fluorescence. For densitometric analysis, the images were collected under constant exposure
parameters. The mVenus signal intensity was determined by the National Institutes of Health ImageJ software. The whole territory of minimum 30 cells was outlined by the Freehand
Line tool and analyzed by taking the sum of the gray values of the pixels in the selection (integrated density) and by subtracting the background. Data were compared by t-test,
p = 6.73E-8.
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4. Discussion
The disordered, highly flexible TPPP/p25 displays both physiolog-
ical and pathological functions determined by its distinct partner pro-
teins such as tubulin and SYN, respectively [3,35]. This pathophysi-
ological moonlighting feature substantiates high conformational plas-
ticity of this protein that is a characteristic feature of chameleon pro-
teins [19]. In addition, our functional studies proved that the binding
segment(s) of the full-length TPPP/p25 could be replaced by other
segments resulting in distinct specificities and/or binding affinities.
We denoted this intriguing phenomenon as the neomorphic chameleon
feature.
Rational drug design is based on the well-defined three-dimen-
sional structures of the globular proteins; however, targeting of dis-
ordered proteins is a challenging task, since these proteins exist in a
highly flexible state forming dynamic structural ensemble without a
well-defined 3D structure. For this reason, assignation of the middle
(CORE) segment of the full length TPPP/p25 by means of multinu-
clear NMR has failed [10]. Different strategies have been suggested
for targeting these versatile IDP proteins [52,53]. A relevant strat-
egy is “to inhibit interactions with ordered or disordered protein part-
ners” [52]. In fact, there are only a limited number of IDP-related sys-
tems studied in drug design; the small molecule inhibitors were mostly
identified by experimental screening without considering the mecha-
nism or the toxic side effects of the inhibition [54,55]. Computational
unfoldomics is a recently proposed, emerging concept, which identi-
fies metastable structures by simulations coupled with virtual screen
of potential inhibitors [53]. In silico high-throughput structure-based
docking screen combined with experiments was successfully applied
to identify a druggable small molecule which ameliorates SYN-me-
diated dysfunction in cell models [56]. These studies are promising;
however, none of them takes into account the effect of the inhibitors
on the physiological functions of IDPs.
Our innovative strategy is based upon the recognition that the
physiological binding interface of TPPP/p25 is distinct from the one
in the pathological TPPP/p25-SYN complex that could ensure high
specificity for drug targeting, e.g., the interface of the pathological
complex may serve as an anti-Parkinson drug target (Fig. 9). The
specificity is further supported by the unique fact that the assembly
of these two disordered hallmarks occurs exclusively at pathological
conditions since in normal brain SYN and TPPP/p25 are expressed in
neurons [57,58] and oligodendrocytes [9,59], respectively. Previously
we showed that TPPP/p25, similarly to SYN, could be taken up by
cells from the medium [35]. In addition, both TPPP/p25 [15] and SYN
[60] were detected in the cerebrospinal fluid of human patients. Ex-
tracellular transmission of these proteins, therefore, is a plausible ex-
planation for the development of pathological inclusions in the case of
Parkinson's disease and multiple system atrophy [16,61,62].
We suggested targeting the interface of the pathological complex
of multifunctional proteins and validating the binding segment as an
innovative strategy for anti-Parkinson drug development. Targeting
by competitors/foldamers should impede/destruct the small soluble as-
semblies, the fatal species in the development of synucleinopathies.
The pathological complex has been suggested functioning as an ini-
tiator in the etiology of Parkinson's disease and multiple system at-
rophy [16–18,61,62]. We explored the challenges associated with tar-
geting chameleon proteins using the TPPP/p25-SYN complex as a
case study. Our studies exemplify that TPPP/p25, as a chameleon pro-
tein with its highly flexible conformation, is known to be involved
in distinct CNS diseases [16], thus the innovative strategy supported
Fig. 9. Distinct interfaces of TPPP/p25 are involved in its hetero-association with tubu-
lin and SYN as physiological and pathological partners, respectively. The interaction of
the disordered TPPP/p25 with tubulin results in significant conformational changes; this
effect does not manifest itself in the case of its association with SYN. In normal brain
the two proteins occur alternatively, in neurons or oligodendrocytes, however, the inclu-
sions due to their pathological assemblies were detected in both cell types in the cases
of Multiple System Atrophy (MSA) and Parkinson's disease (PD). Although the dele-
tions within the CORE segments do not diminish the binding of TPPP/p25 mutants to
SYN, except in the case of the double truncated double loop mutant (DTDL), due to its
chameleon feature; however, multiple segments were identified as potential drug target
which are distinct from the segment responsible for the association with tubulin.
by these studies could contribute to our understanding the pathomech-
anism of the Parkinson's and other related diseases.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2016.09.017.
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